Ardelyx Inc
ARDX
View Detailed Chart
6.313USD
+0.123+1.99%
Market hours （ET）Quotes delayed by 15 min
1.52BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.99%
5 Days
-4.92%
1 Month
+5.75%
6 Months
+16.48%
Year to Date
+24.52%
1 Year
+2.65%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Buy
Current Rating
11.182
Target Price
+74.17%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 539.62% year-on-year.
Undervalued
The company’s latest PE is -26.42, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 180.23M shares, increasing 3.09% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 15.98M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Ticker SymbolARDX
CompanyArdelyx Inc
CEOMr. Michael G. (Mike) Raab
Websitehttps://www.ardelyx.com/
Related Instruments
-0.61%
-3.55%
+2.16%
+0.88%
+0.13%
+0.84%
+1.45%
+0.82%
+2.54%
+1.04%
-0.53%
-0.64%
+0.90%
+0.98%
+0.49%
+1.20%
+3.00%
0.00%
+0.89%
+3.19%
